Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED

Characterization of Methylation Patterns in Cancer and Non-Cancer cfDNA

NCT04264767 · View on ClinicalTrials.gov ↗

Study Summary

Nucleix EpiCheck® tests analyzes the methylation pattern in a panel of DNA methylation biomarkers and determines whether this pattern is consistent with cancer under test or with non-cancer tissue. This study is being performed as part of the development process of the Pan Cancer EpiCheck test which includes the identification of different methylation profiles in various cancer types and healthy controls.

Interventions

  • PROCEDURE Blood collection

Study Locations (3)

California

  • Los Angeles Hematology Oncology Medical Group - Wilson Terrace — Glendale
  • Los Angeles Hematology Oncology Medical Group - Good Samaritan Medical Offices — Los Angeles

Other

  • Sourasky Medical Center — Tel Aviv

Trial Details

FieldValue
Enrollment Target 800 participants
Start Date 2019-04-17
Est. Completion 2021-01-30

Sponsor

Nucleix

3 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04264767

The ClinicalTrials.gov registry entry for NCT04264767 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nucleix, which has 3 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 3 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention — of which Blood collection is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT04264767 reports 3 study locations spanning 2 distinct geographic areas — top geographies include California, Other. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT04264767 about?

NCT04264767 is a clinical study titled "Characterization of Methylation Patterns in Cancer and Non-Cancer cfDNA". Nucleix EpiCheck® tests analyzes the methylation pattern in a panel of DNA methylation biomarkers and determines whether this pattern is consistent with cancer under test or with non-cancer tissue. This study is being performed as part of the development process of the Pan Cancer EpiCheck test whic...

What is the current status of trial NCT04264767?

This trial is currently completed. The enrollment target is 800 participants. The study started on 2019-04-17. Estimated completion is 2021-01-30.

What conditions does trial NCT04264767 study?

This clinical trial studies the following conditions: Cancer, Solid Tumor, Hematologic Neoplasms. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT04264767?

The interventions under investigation include: Blood collection (PROCEDURE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT04264767?

This trial is sponsored by Nucleix, which has 3 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT04264767 being conducted?

This trial has 3 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial